Furthermore, CD56+ monocyte-derived IL-15 DCs possess a more pronounced lytic effector function toward tumor cells as compared to their CD56− counterparts, accompanied by elevated TRAIL and granzyme B levels, as well as a superior antigen-presenting capacity (75). This evidence concerns the gene TNFSF10 and neoplasm.